The REWIND (Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes) trial27 was designed to only evaluate the superiority of dulaglutide in reducing adverse CV outcomes in a low CV risk population, making it one of the first primary prevention studies for GLP-1R agonists. Here, GLP1R is linked to type 2 diabetes mellitus.